Drug Discovery Assay – reference number: B117
This experiment assesses whether test articles cause inflammatory cytokine release in healthy skin, with lipopolysaccharide (LPS) as a reference compound. It uses healthy skin punch biopsies to explore test article effect on the expression on inflammatory cytokines via ELISA and/or rtPCR.
Assay Type: | Skin |
Tissue: | Human Skin Biopsies (Healthy) |
Target: | Study Dependant |
Control Compound: | LPS |
Study Type: | Ex vivo cultures |
Functional Endpoint: | Inflammation |
The specific results that will be provided are on the inflammatory effect of test articles in human fresh skin.
For a standard experiment with n=3, tissue procurement is estimated to be 8-10 weeks. These timelines are a guide based on standard tissue criteria; any client-imposed alterations to the criteria may alter these estimates.
Test article(s) to be provided by the Sponsor in storable aliquots at required test concentrations with information on diluent vehicle used. Stock solutions are prepared in deionized water unless otherwise requested. Sponsor to provide sufficient test article to run the entire study.
We suggest test conditions are assessed in triplet as a minimum.
Full-thickness skin biopsies are achieved via punch-biopsy of residual surgical tissue. Biopsies are taken at a size of 3mm2 and transferred into fortified media, leaving the epidermis exposed to air. Biopsies are incubated in optimum conditions for a maximum of 72 hrs. Tissue media is collected for phenotype analysis by ELISA and/or the biopsy set is collected for rtPCR.
An example of the conditions assessed for 3 test articles are detailed below (it is recommended a minimum of triplicates should be used for each condition):
Full-thickness skin biopsies are achieved via punch-biopsy of residual surgical tissue. Biopsies are taken at a size of 8mm2 and transferred into specially fortified media, leaving the epidermis exposed to air. Biopsies are incubated in optimum conditions for a maximum of 72 hrs. Tissue media is collected for phenotype analysis by ELISA and/or the biopsy set is collected for rtPCR.
An example of the conditions assessed for 3 test articles are detailed below (it is recommended a minimum of triplicates should be used for each condition):
No specific exclusion criteria are in place other than to reject macroscopically diseased/necrotic tissue.
Tissue that does not respond to stimulation with the positive control would be deemed non-functional.
Cytokine analysis: Supernatant samples can be analyzed for specific analytes of your choice by a multiplex ELISA platform. Each analyte will be quantified by interpolation against a standard curve generated on the same 96 well analysis plate.
Other forms of end point analysis are available such as gene expression or immunohistochemistry.
Normal Skin Histopathology Maintained for up to One Week in Culture
Back to the Drug Discovery Assay Catalog »
Predictive Drug Discovery Assay Services
Online Resources
22-25 March 2021 / Virtual Meeting
We are participating in Europe’s largest Springtime Biotech Partnering Digital Event. Please schedule a virtual meeting with us!
16 February 2021
17 December 2020
10 December 2020
REPROCELL
Products
Services
© 2021 REPROCELL Inc. All rights reserved.
REPROCELL Inc. 日本語 MetLife Shin-yokohama 381, Bldg. 9F, 3-8-11 Shin-yokohama, Kohoku-ku, Yokohama, Kanagawa 222-0033, Japan
REPROCELL USA Inc. 9000 Virginia Manor Road, Suite 207, Beltsville, 20705, USA
REPROCELL Europe Ltd. Thomson Pavilion, Todd Campus, West of Scotland Science Park, Acre Road, Glasgow, G20 0XA, United Kingdom
Bioserve Biotechnologies (India) PVT Ltd. Unit: D4-D7, 1st Floor, Industrial Estate, Moula Ali, Medchal-Malkajgiri Dist., Hyderabad-500040, Telangana, India